ライフサイエンスコーパス: matrix metalloproteinase inhibitor

1 ed hepatitis, even after pretreatment with a matrix metalloproteinase inhibitor.

2 restored bone resorption in the presence of matrix metalloproteinase inhibitors.

3 These data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents

4 th movement can be inhibited with the use of matrix metalloproteinase inhibitors, and suggests a mech

5 p (SAR) studies of a series of proline-based matrix metalloproteinase inhibitors are described.

6 lN/LPS- or Con A-induced hepatitis, and that matrix metalloproteinase inhibitors are ineffective in p

7 Sensitivity to known matrix metalloproteinase inhibitors as well as to the en

8 The addition of a matrix metalloproteinase inhibitor attenuated NKp46 down

9 It is likely that adjuvant use of matrix metalloproteinase inhibitors can significantly en

10 antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazol

11 However, administration of a matrix metalloproteinase inhibitor exacerbates liver inj

12 In vitro, the matrix metalloproteinase inhibitor FN-439 promoted survi

13 Daily administration of the broad-spectrum matrix metalloproteinase inhibitor Galardin for 3 days i

14 bited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001).

15 Here we report that a matrix metalloproteinase inhibitor, GM-6001, improves su

16 Interestingly, the matrix metalloproteinase inhibitor GM6001 (ilomastat), w

17 lease of EGFR ligands, as the broad-spectrum matrix metalloproteinase inhibitor GM6001 could inhibit

18 ibiting ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in ac

19 97, the HB-EGF neutralizing antibody, or the matrix metalloproteinase inhibitor GM6001.

20 tes the growth suppression properties of the matrix metalloproteinase inhibitor GM6001.

21 with methylprednisolone and a broad-spectrum matrix metalloproteinase inhibitor (GM6001) did not deve

22 ptor (EGFR) inhibitor (tyrphostin AG1478), a matrix metalloproteinase inhibitor (GM6001), or a hepari

23 Recently, a class of matrix metalloproteinase inhibitors has been identified

24 Interferons, matrix metalloproteinase inhibitors, imatinib and gefiti

25 General matrix metalloproteinase inhibitors limited the resorpti

26 ell invasion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in p

27 lso were accelerated with the broad-spectrum matrix metalloproteinase inhibitor Marimastat, which may

28 idal obstruction syndrome, establishing that matrix metalloproteinase inhibitors may be a therapeutic

29 The hypothesis that matrix metalloproteinase inhibitors may be useful for ex

30 Matrix metalloproteinase inhibitors (MMPIs) reduce blood

31 and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designe

32 oMFA) for a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs).

33 nd FasL-converting enzyme, can be blocked by matrix metalloproteinase inhibitors (MMPIs).

34 sclerosis using technetium-99m-labeled broad matrix metalloproteinase inhibitor (MPI) and to determin

35 Technetium-99m-labeled matrix metalloproteinase inhibitor (MPI) was used for th

36 ed to elucidate the effect of doxycycline, a matrix metalloproteinase inhibitor, on cardiac injury an

37 and vascular endothelial growth factor) and matrix metalloproteinase inhibitor (plasminogen activato

38 matrix metalloproteinases with a broad-based matrix metalloproteinase inhibitor prevented LV dilation

39 ng directional filopodial extension, whereas matrix metalloproteinase inhibitors prevented sprout ext

40 Administration of matrix metalloproteinase inhibitors prevented the signs

41 Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix met

42 have demonstrated that treating tumors with matrix metalloproteinase inhibitors results in tumor red

43 uction of mitogenic signaling by PDGF-B in a matrix metalloproteinase inhibitor-sensitive fashion.

44 F impaired ARPE-19 migration toward HGF in a matrix metalloproteinase inhibitor-sensitive manner.

45 Thus, localized induction of endogenous matrix metalloproteinase inhibitors, such as TIMP-4, hol

46 Interferons, matrix metalloproteinase inhibitors, thalidomide, bevaci

47 mulated the search for a number of synthetic matrix metalloproteinase inhibitors that could serve as

48 remote and border zones at 3 months, and the matrix metalloproteinase inhibitor TIMP-4 increased dram

49 vidence suggests that elevated levels of the matrix metalloproteinase inhibitor, tissue inhibitor of

50 The ability of several specific matrix metalloproteinase inhibitors to reduce outflow fa

51 When BB-94, a matrix metalloproteinase inhibitor, was added to the cul

52 tide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied.

53 Ilomastat, agents initially characterized as matrix metalloproteinase inhibitors which are in early s

54 ed by local delivery of Ilomastat, a general matrix metalloproteinase inhibitor, with the use of ethy